Th e last decade has been a proverbial roller-coaster ride for irritable bowel syndrome (IBS) patients and the providers who care for them. We have experienced the exhilarating highs of exciting, new IBS treatment developments, all too oft en followed by the free fall of promising medications failing to attain the Food and Drug Administration (FDA) approval ( 1,2 ), being withdrawn from the US market over adverse-eff ect concerns ( 3,4 ) or complicated by stipulations of the Prescriber Program enrollment for use ( 5,6 ). Re-equilibrating from this dizzying trip, we now fi nd that, presently, lubiprostone stands alone as the only remaining FDA-approved medication for use in constipation-predominant IBS (IBS-C) patients ( 7 ).
endpoint of " adequate relief " or " satisfactory relief " with therapy ( 16 -18 ) , or a Likert-based " subject global assessment of relief " ( 19 ) . Such global assessment items, although reproducible and responsive to changes in clinical status, have been criticized for a lack of detailed assessment of individual IBS symptoms ( 20 -24 ) . In 2010, the FDA endorsed a co-primary IBS response endpoint that comprised both abdominal pain intensity and defecation measures ( 9 ) . Th is new endpoint was justifi ed on the grounds that IBS is a symptom-based diagnosis, which, by defi nition, involves abdominal pain / discomfort in association with defecatory issues ( 25 ) ; thus, it was decided that primary outcome measures should systematically assess each of these core symptoms individually. One distinct disadvantage to this combined FDA endpoint is the presumption that abdominal pain intensity and bowel frequency are the symptoms uniformly held by all IBS patients as the principal targets of any therapeutic intervention. However, clinical intuition suggests, and indeed objective studies confi rm, that IBS patients experience diffi culties with a variety of symptoms, including bloating, straining, fl atulence, and altered stool consistency, to name a few ( 26 -28 ) . Some IBS patients do not identify with the experience of pain at all, rather relating symptoms of " discomfort " or " cramping " . When pain is endorsed, it is oft en a multidimensional experience, not limited to a spectrum of intensity alone, but also qualifi ed by other key descriptors, such as bothersomeness, predictability, frequency, and impact on function ( 26 ) . Considering the complexity and diversity of the IBS symptom experience, a contrarian view might hold that although admittedly less specifi c, the global IBS measures supplanted by the FDA co-primary endpoint are actually superior at capturing holistically the IBS symptom experience.
In this climate of shift ing endpoints, how should the clinician then interpret these data on the effi cacy of linaclotide relative to our IBS-C patients? Some additional insights may be gained by fi rst examining the data regarding individual IBS symptoms. Th e data on linaclotide ' s impact on bowel frequency are reasonably straightforward; the studies by Rao et al. ( 29 ) and Chey et al. ( 30 ) fi nd that the previously observed benefi t of linaclotide in chronic constipation extends to IBS-C populations ( 11 ) . Both IBS-C trials observed a mean increase of over 2 CSBMs a week with linaclotide, an impressive gain from a baseline mean of only 0.2 CSBMs per week at study onset. Applying the FDA defi nition of " improvement " in bowel frequency as an increase ≥ 1 CSBM per week from baseline in at least 6 of the fi rst 12 of the study weeks ( 9 ) , both studies achieved this endpoint in just less than one-half of linaclotide recipients. Very respectable numbers needed to treat (NNT) result, and suggest that four to fi ve patients would need to be treated with linaclotide to achieve one FDA-defi ned improvement in bowel frequency. Th e Chey et al. study also suggests that this bowel frequency response to linaclotide is durable, with nearly 90 % of the overall constipation benefi t seen in the fi rst 12 weeks still persisting at week 26.
In terms of pain response, both phase 3 trials demonstrated that signifi cantly greater numbers of IBS-C patients reported decreases in maximal pain intensity (FDA defi ned as a ≥ 30 % improvement in abdominal pain intensity from baseline in 6 of 12 study movements, or CSBMs ( 9 ) . Th e main design diff erences in these two trials relate to study duration, with Chey et al. reporting on a 26-week total treatment period, whereas Rao et al. treated IBS-C patients with linaclotide or placebo for 12 weeks, followed by a 4-week randomized withdrawal period. Th rough the data collected in these two clinical trials, the gastroenterology community now seeks to answer several critical questions regarding linaclotide as a potential new treatment option in IBS-C.
Given the recent troubling experiences with adverse events relating to IBS pharmacotherapies, the foremost amongst the priorities must be an eff ort to convincingly address any concerns about the safety of linaclotide. From a pharmacokinetic perspective, the initial reassurances regarding linaclotide ' s safety emerged from animal model studies, suggesting a very low oral bioavailability of linaclotide and its active metabolites (0.1 % ) ( 10 ) . Th ese data seemingly would make the systemic toxicity that has plagued some of linaclotide ' s predecessors less likely. Th e clinical trial data presented in this issue of American Journal of Gastroenterology , along with phase 2b and phase 3 data on linaclotide in chronic constipation patients, now represent a collective experience of over 500 patient-years of linaclotide therapy ( 11 -13 ) . Across these studies, serious adverse events were few ( < 1.0 % of subjects), were not signifi cantly greater than rates seen with placebo, and were in no case conspicuously linked to linaclotide. However, in the current trials, treatment-emergent adverse events (TEAEs) were reported by over one-half of those receiving linaclotide, the most noteworthy being a statistically signifi cant greater incidence of diarrhea in one of fi ve subjects. Th ese observations relate to the secretagogue mechanism of the drug ( 14 ) , and refl ect the relatively narrow therapeutic window common to such agents, including the chloride-channel agonist, lubiprostone ( 15 ) . Although minor TEAEs led to medication discontinuation in only a small percentage of those treated with linaclotide, more widespread clinical experience will further clarify to what extent these minor adverse eff ects may limit patient acceptance of this medication.
Safety concerns addressed, we can now consider the more interesting questions relating to linaclotide effi cacy in IBS-C. Here, all eyes initially should focus on the combined FDA " response " endpoint. Aft er all, the FDA approval of linaclotide for use in IBS-C (currently under FDA review) will hinge largely on this key endpoint, mandating improvements in both abdominal pain intensity ( ≥ 30 % from average daily worst pain score) and complete spontaneous bowel movements ( ≥ 1 CSBM from baseline) for at least one-half of the total study weeks ( 9 ). In short, both studies successfully demonstrated nearly identical FDA response rates of just over one-third of IBS-C subjects receiving linaclotide. Accounting for placebo responses, these data suggest that around fi ve to eight IBS-C subjects would need to be treated with linaclotide to achieve a single FDA-defi ned responder. Placing this FDA response data on linaclotide in the context of other contemporary IBS clinical trials is challenging, as this provisional FDA endpoint represents a departure from previous IBS studies conducted over the past decade. Earlier IBS clinical trials predominantly utilized either a binary (yes / no) weeks), with linaclotide compared with placebo. Chey et al. and Rao et al. consistently found that around 50 % IBS-C subjects treated with linaclotide reached this FDA pain-improvement endpoint. Recalling that 50 % of linaclotide recipients similarly reached the bowel frequency endpoint, one might initially conclude that the observed improvement in abdominal pain with linaclotide is simply a downstream eff ect of gains in intestinal transit and bowel frequency. However, this notion is dispelled by re-examining this data in the context of the combined FDA endpoint, where it was found that improvements in both abdominal pain and bowel frequency were reached only in one out of three patients receiving linaclotide. Th ese discrepancies between the FDA-combined endpoint and individual symptom response rates suggest that a number of linaclotide patients (around 16 % overall, or one in three pain responders) will experience improvements in abdominal pain intensity without improvement in bowel frequency ( Figure 1 ). Th ese data allow for several interpretations. First, these fi ndings could be viewed as providing indirect evidence in support of animal studies, suggesting a second benefi t of linaclotide in the extracellular inhibition of pain fi ber activity ( 31 ) . On the other hand, some patients (14.5 % of linaclotide recipients) seem to experience only laxative eff ects, without enjoying the benefi t of a meaningful pain response. Drawing a fi rm conclusion from these data is even more of a challenge when considering the phase 3 data on linaclotide in chronic constipation. Lembo and colleagues ( 11 ) found that almost one-third of chronic constipation patients treated with linaclotide reported a decrease in abdominal discomfort, this in a condition not typically associated with visceral hypersensitivity ( 11, 25 ) . Th ese observations highlight the need for additional research to better understand the pharmacology and mechanisms of action of linaclotide. Still, some of the uncertainly inherit in these observations will likely remain, in part relating to the challenge of optimally defi ning (and measuring) the core IBS symptoms of pain and abnormal defecation.
Finally, although assessments of additional IBS symptoms have been relegated to a status of lesser import as secondary endpoints, both phase 3 linaclotide studies nevertheless did examine several accessory IBS-C symptoms worth mentioning. In both reports, nearly 50 % of IBS-C subjects endorsed signifi cant decreases in abdominal discomfort, bloating, cramping, and fullness for at least one-half of the study weeks. Statistical improvements over placebo in straining, stool consistency, and constipation severity scores also were observed. Th ough these symptoms are important to the irritable bowel patient, measures of these symptoms remain unproven as independent variables in IBS-C clinical trials. As such, we continue to rely on validated global measures as proxy assessments of these accessory symptoms, in combination with core pain and defecatory symptoms. Each of the current protocols did collect global response data via an " adequate relief " question, and again found that approximately one-half of linaclotide patients reported adequate relief of symptoms in at least 6 weeks of the initial 12 study weeks. Accounting for placebo responders, NNTs of 3.4 -6.8 to achieve adequate relief were calculated in the two studies. Adequate relief remains the best measure to allow for the comparison of these phase 3 results with linaclotide with the other recent studies of IBS-C, all of which employed global assessments of relief. With NNT from recent IBS clinical trials as a precedent (e.g., lubiprostone, NNT 12.8; tegaserod, NNT 7.9) the linaclotide data presented in these two studies should be compelling when reviewed by regulatory agencies ( 16, 18, 19, 32 ) .
Looking toward the future of linaclotide in the treatment of IBS-C, several important knowledge gaps remain. First, we need to more clearly establish the role of linaclotide in the context of the other IBS-C treatments, including lubiprostone. It will be important to learn whether linaclotide is superior to lubiprostone and, moreover, whether patients unresponsive to one of these agents will potentially benefi t from switching to the other secretagogue. And, as linacotide appears to confer a benefi t to only a portion of IBS-C patients, gastroenterologists will need to establish a more precise understanding of who exactly the " linaclotide responders " are, not only in terms of bowel pattern and IBS symptom severity, but also relevant physiologic and non-gastrointestinal clinical factors, such as psychiatric co-morbidity. Given the heterogeneity of symptom experiences among IBS patients, the ideal primary endpoint to study novel IBS treatments will likely never be fully unattainable. However, eff orts of the Patient Reported Outcome Consortium are underway as a part of a joint public -private venture, in an attempt to bring greater clarity into IBS patient symptom experiences, and hopefully to improve future approaches to the assessment of IBS symptoms in the context of clinical trials ( 33 ) . In the interim, real-world experiences will soon clarify for the gastroenterology community whether the objective improvement in portions of the IBS-C symptom experience, as detected using the provisional FDA endpoint, will translate clinically into linaclotide ' s emergence as a new therapeutic agent promising " true improvements " in those living with IBS. 
